Drug Type Cell therapy |
Synonyms- |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 1 | US | 26 Oct 2020 | |
Hematopoietic stem cell transplantation | Phase 1 | US | 26 Oct 2020 | |
Mantle-Cell Lymphoma | Phase 1 | US | 26 Oct 2020 | |
Multiple Myeloma | Phase 1 | US | 26 Oct 2020 | |
Myelodysplastic Syndromes | Phase 1 | US | 26 Oct 2020 | |
Peripheral T-Cell Lymphoma | Phase 1 | US | 26 Oct 2020 | |
Residual Neoplasm | Phase 1 | US | 26 Oct 2020 | |
Smith-Magenis Syndrome | Phase 1 | US | 26 Oct 2020 |
Early Phase 1 | Relapsing acute myeloid leukemia | Treatment related acute myeloid leukaemia | Acute Lymphoblastic Leukemia | Hematopoietic stem cell transplantation | Diffuse large B-cell lymphoma recurrent | Mantle-Cell Lymphoma | Diffuse large B-cell lymphoma refractory | Smith-Magenis Syndrome | Multiple Myeloma | Residual Neoplasm | Recurrent Hematologic Malignancy | T-cell lymphoma refractory | T-cell lymphoma recurrent | Myelodysplastic Syndromes | 2 | Allogeneic Hematopoietic Stem Cell Transplantation+Irradiated Allogeneic Cells (Cohort I (Initial IHC Within 42 Days)) | bvparvnhzs(wuejuzngmp) = jgmkiqqcut tyqhxnczev (ruevcnidsv, aztwfciyoh - sowrstrvuy) View more | - | 26 Jun 2023 | |
Allogeneic Hematopoietic Stem Cell Transplantation+Irradiated Allogeneic Cells (Cohort II (Initial IHC Within 70 Days or After Relapse)) | wumhpuhlgj(nzcdejxjte) = xwtwgopmcm ldmpirzyqz (qwdhfcxone, frmwdasstm - qbolukhucg) View more |